Literature DB >> 26491894

Current Status of Hybrid PET/MRI in Oncologic Imaging.

Andrew B Rosenkrantz1, Kent Friedman1, Hersh Chandarana1, Amy Melsaether1, Linda Moy1, Yu-Shin Ding1, Komal Jhaveri2,3, Luis Beltran1, Rajan Jain1.   

Abstract

OBJECTIVE: This review article explores recent advancements in PET/MRI for clinical oncologic imaging.
CONCLUSION: Radiologists should understand the technical considerations that have made PET/MRI feasible within clinical workflows, the role of PET tracers for imaging various molecular targets in oncology, and advantages of hybrid PET/MRI compared with PET/CT. To facilitate this understanding, we discuss clinical examples (including gliomas, breast cancer, bone metastases, prostate cancer, bladder cancer, gynecologic malignancy, and lymphoma) as well as future directions, challenges, and areas for continued technical optimization for PET/MRI.

Entities:  

Keywords:  MRI; PET; cancer; hybrid PET/MRI

Mesh:

Substances:

Year:  2015        PMID: 26491894      PMCID: PMC4915069          DOI: 10.2214/AJR.15.14968

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  82 in total

1.  PET-MRI hybrid imaging in a rare case of B cell lymphoblastic lymphoma with musculoskeletal manifestation.

Authors:  Ruth Eichner; Markus Essler; Katja Specht; Klaus Wörtler; Christian Peschel; Florian Bassermann; Ingo Ringshausen
Journal:  Ann Hematol       Date:  2013-06-18       Impact factor: 3.673

2.  MR-compatibility assessment of the first preclinical PET-MRI insert equipped with digital silicon photomultipliers.

Authors:  J Wehner; B Weissler; P M Dueppenbecker; P Gebhardt; B Goldschmidt; D Schug; F Kiessling; V Schulz
Journal:  Phys Med Biol       Date:  2015-02-16       Impact factor: 3.609

Review 3.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

4.  Potential of hybrid ¹⁸F-fluorocholine PET/MRI for prostate cancer imaging.

Authors:  Thomas de Perrot; Olivier Rager; Max Scheffler; Martin Lord; Marc Pusztaszeri; Christophe Iselin; Osman Ratib; Jean-Paul Vallee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-20       Impact factor: 9.236

Review 5.  Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.

Authors:  Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce O'shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

Review 6.  PET, PET/CT, and PET/MR Imaging Assessment of Breast Cancer.

Authors:  Shamim Ahmed Shamim; Drew A Torigian; Rakesh Kumar
Journal:  PET Clin       Date:  2009-06-21

Review 7.  Whole-body FDG PET-MR oncologic imaging: pitfalls in clinical interpretation related to inaccurate MR-based attenuation correction.

Authors:  Ulrike Attenberger; Ciprian Catana; Hersh Chandarana; Onofrio A Catalano; Kent Friedman; Stefan A Schonberg; James Thrall; Marco Salvatore; Bruce R Rosen; Alexander R Guimaraes
Journal:  Abdom Imaging       Date:  2015-08

Review 8.  Imaging approaches with advanced prostate cancer: techniques and timing.

Authors:  David Leung; Saravanan Krishnamoorthy; Lawrence Schwartz; Chaitanya Divgi
Journal:  Can J Urol       Date:  2014-04       Impact factor: 1.344

Review 9.  Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations.

Authors:  Hossein Jadvar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  25 in total

Review 1.  Potential Role of PET/MRI for Imaging Metastatic Lymph Nodes in Head and Neck Cancer.

Authors:  Sungheon Gene Kim; Kent Friedman; Sohil Patel; Mari Hagiwara
Journal:  AJR Am J Roentgenol       Date:  2016-05-10       Impact factor: 3.959

Review 2.  Is There Use for FDG-PET in Prostate Cancer?

Authors:  Hossein Jadvar
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

Review 3.  The use of PET/MRI for imaging rectal cancer.

Authors:  Thomas A Hope; Zahra Kassam; Andreas Loening; Michelle M McNamara; Raj Paspulati
Journal:  Abdom Radiol (NY)       Date:  2019-11

Review 4.  [The role of the vesical imaging-reporting and data system (VI-RADS) for bladder cancer diagnostics-status quo].

Authors:  V Hechler; M Rink; D Beyersdorff; M Beer; A J Beer; V Panebianco; M Pecoraro; C Bolenz; G Salomon
Journal:  Urologe A       Date:  2019-12       Impact factor: 0.639

5.  Simultaneous PET/MRI in assessing the response to chemo/radiotherapy in head and neck carcinoma: initial experience.

Authors:  Valeria Romeo; Brigida Iorio; Massimo Mesolella; Lorenzo Ugga; Francesco Verde; Emanuele Nicolai; Mario Covello
Journal:  Med Oncol       Date:  2018-06-19       Impact factor: 3.064

6.  Prospective Pilot Study to Evaluate the Incremental Value of PET Information in Patients With Bladder Cancer Undergoing 18F-FDG Simultaneous PET/MRI.

Authors:  Andrew B Rosenkrantz; Kent P Friedman; Fabio Ponzo; Roy A Raad; Kimberly Jackson; William C Huang; Arjun V Balar
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

7.  Current Status and Future Directions for Screening Patients at High Risk for Pancreatic Cancer.

Authors:  Florencia McAllister; Maria F Montiel; Guneesh S Uberoi; Angad S Uberoi; Anirban Maitra; Manoop S Bhutani
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-05

8.  Simultaneous PET/MRI assessment of response to cytotoxic and hormone neo-adjuvant chemotherapy in breast cancer: a preliminary report.

Authors:  Valeria Romeo; Massimiliano D'Aiuto; Giuseppe Frasci; Massimo Imbriaco; Emanuele Nicolai
Journal:  Med Oncol       Date:  2016-12-30       Impact factor: 3.064

9.  Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer.

Authors:  Sascha Kaufmann; Stephan Kruck; Sergios Gatidis; Tobias Hepp; Wolfgang M Thaiss; Jörg Hennenlotter; Johannes Schwenck; Marcus Scharpf; Konstantin Nikolaou; Arnulf Stenzl; Gerald Reischl; Christian la Fougère; Jens Bedke
Journal:  World J Urol       Date:  2020-01-06       Impact factor: 4.226

10.  Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer.

Authors:  Bang-Bin Chen; Yu-Wen Tien; Ming-Chu Chang; Mei-Fang Cheng; Yu-Ting Chang; Shih-Hung Yang; Chih-Horng Wu; Ting-Chun Kuo; I-Lun Shih; Ruoh-Fang Yen; Tiffany Ting-Fang Shih
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.